Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qishen Yiqi Dropping Pills + targeted therapy refers to a combination treatment regimen being evaluated for severe pulmonary hypertension. Qishen Yiqi Dropping Pills (QSYQ) is a Chinese patent medicine approved by the NMPA for cardiovascular conditions, containing extracts from *Astragalus membranaceus*, *Salvia miltiorrhiza*, *Panax notoginseng*, and *Dalbergia odorifera*. The targeted therapy component consists of standard-of-care agents for pulmonary arterial hypertension (PAH), such as endothelin receptor antagonists (ERAs), phosphodiesterase type 5 (PDE5) inhibitors, or soluble guanylate cyclase (sGC) stimulators. This combination aims to provide synergistic effects by combining the vasodilatory and remodeling-inhibitory actions of targeted drugs with the cardioprotective, anti-inflammatory, and microcirculation-enhancing properties of QSYQ. Clinical research, such as trials led by Guangdong Provincial People's Hospital, focuses on improving exercise capacity, heart function, and quality of life in patients with severe PAH.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qishen Yiqi Dropping Pills + targeted therapy.